It selectively inhibits the microRNA virus polymerase of infected cells, inhibits the RNA polymerase that depends on the virus code, and blocks the synthesis of viral RNA, thereby inhibiting the virus. It can effectively inhibit various strains of human enterovirus, Coxsackie virus, polio virus, and acute epidemic hemorrhagic tuberculosis and keratitis (commonly known as "pink eye") virus (Shanghai-17 strain).

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. Poor antibacterial activity against anaerobic bacteria. Ciprofloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.

This product is a broad-spectrum antibacterial agent. Its mechanism of action is to compete with para-aminobenzoic acid (PABA) in bacteria, inhibit dihydrofolate synthase, and thus hinder the growth and reproduction of bacteria.